The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D. Heightened awareness and robust support from governments and key industry players further create a dynamic environment for innovation and better patient outcomes.
LAS VEGAS, Dec. 3, 2024 /PRNewswire/ -- DelveInsight's 'Lupus Nephritis Pipeline Insight 2024 [https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]' report provides comprehensive global coverage of pipeline lupus nephritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the lupus nephritis pipeline domain.
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg [https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg]
Key Takeaways from the Lupus Nephritis Pipeline Report
-- DelveInsight's lupus nephritis pipeline report depicts a robust space
with 30+ active players working to develop 35+ pipeline therapies for
lupus nephritis treatment.
-- Key lupus nephritis companies such as AstraZeneca, Hoffmann-La Roche,
Novartis, Qilu Pharmaceutical, Vera Therapeutics, Conduit
Pharmaceuticals, Amgen, Johnson & Johnson, BeiGene, RemeGen, Argenx,
Kyverna Therapeutics, Cabaletta Bio, ImmPACT Bio, Alpine Immune
Sciences, AlloSite Therapeutics, iCell Gene Therapeutics, Caribou
Biosciences, Adicet Bio, Shenzhen Pregene Biopharma Co., Ltd., Resolve
Therapeutics, BioAegis Therapeutics, Lepton Pharmaceuticals, Transcenta
Holding, and others are evaluating new lupus nephritis drugs to improve
the treatment landscape.
-- Promising lupus nephritis pipeline therapies such as Anifrolumab,
Obinutuzumab, Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab,
Nipocalimab, Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101,
CABA-201, IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010,
ADI-001, PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008,
TST 008, and others are under different phases of lupus nephritis
clinical trials.
-- In November 2024, Adicet Bio announced that the first LN patient had
been dosed in the Phase I clinical trial evaluating ADI-001 in
autoimmune diseases.
-- In November 2024, Kyverna Therapeutics announced that it would present
updated clinical data from LN patients treated with KYV-101 in ongoing
Kyverna-sponsored KYSA-1 and KYSA-3 Phase I/II studies and named patient
treatments.
-- In October 2024, Kezar Life Sciences suspended subject enrolment and
patient dosing in the Phase II PALIZADE trial of zetomipzomib for active
lupus nephritis.
-- In June 2024, Nkarta announced the initiation of Ntrust-I, a
multi-center clinical trial of NKX019 in lupus nephritis, with the first
patient in screening. The company also announced the clearance by the
U.S. Food and Drug Administration (FDA) of its second Investigational
New Drug (IND) application for NKX019 in autoimmune disease.
-- In June 2024, Adicet Bio announced that the US Food and Drug
Administration (FDA) had granted Fast Track Designation to ADI-001 for
the potential treatment of relapsed/refractory class III or class IV
lupus nephritis.
-- In April 2024, Caribou Biosciences announced that it had received
clearance of its Investigational New Drug (IND) application from the
U.S. Food and Drug Administration (FDA) for CB-010, an allogeneic
anti-CD19 CAR-T cell therapy with a PD-1 knockout (KO), for the
treatment of lupus nephritis (LN) and extrarenal lupus (ERL). The Phase
1, multicenter, open label GALLOP clinical trial of CB-010 in patients
with LN and ERL is expected to initiate by year-end 2024.
-- In March 2024, Artiva Therapeutics is looking to dose the first patient
in a Phase I/II trial assessing its cell therapy AlloNK in lupus
nephritis (LN).
Request a sample and discover the recent advances in lupus nephritis treatment drugs @ Lupus Nephritis Pipeline Report [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
The lupus nephritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lupus nephritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lupus nephritis clinical trial landscape.
Lupus Nephritis Overview
Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease that can affect multiple organ systems. In lupus nephritis, the immune system mistakenly attacks the kidneys, leading to inflammation and damage. The exact cause is not fully understood, but it is believed to involve a combination of genetic, hormonal, and environmental factors, including infections and exposure to certain drugs or UV light.
Symptoms of lupus nephritis can vary but often include swelling in the legs and feet, high blood pressure, foamy urine, and in severe cases, hematuria. Patients may also experience fatigue, joint pain, and skin rashes, typical of lupus. Diagnosis usually involves a combination of blood tests, urinalysis, and imaging studies. A kidney biopsy may be necessary to evaluate the extent of kidney damage and guide treatment.
Treatment for lupus nephritis aims to reduce inflammation and prevent kidney damage. It often involves corticosteroids and immunosuppressive medications such as mycophenolate mofetil or azathioprine. In severe cases, more aggressive treatments, including cyclophosphamide or biologic therapies like belimumab, may be utilized. Regular monitoring of kidney function and overall health is crucial for managing the disease effectively.
Find out more about lupus nephritis treatment drugs @ Drugs for Lupus Nephritis Treatment [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
A snapshot of the Lupus Nephritis Pipeline Drugs mentioned in the report:
Drugs Company Phase MoA RoA Anifrolumab AstraZeneca Phase III Interferon alpha-beta receptor antagonists Intravenous Ianalumab Novartis Phase Antibody-dependent cell cytotoxicity; B-cell activation factor III receptor antagonists Subcutaneous ADX-097 Q32 Bio Phase II Complement C3 inhibitors Subcutaneous KZR 616 Kezar Life Sciences Phase II Proteasome inhibitors Subcutaneous TAK-007 Takeda Phase I Immunologic cytotoxicity; Natural killer cell replacements Intravenous NKX019 Nkarta Therapeutics Phase I Immunologic cytotoxicity; Natural killer cell replacements Intravenous ATA3219 Atara Biotherapeutics Phase I Immunologic cytotoxicity; T lymphocyte replacements Intravenous
Learn more about the emerging lupus nephritis pipeline therapies @ Lupus Nephritis Clinical Trials [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Lupus Nephritis Therapeutics Assessment
The lupus nephritis pipeline report proffers an integral view of the lupus nephritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Lupus Nephritis Pipeline Report
-- Coverage: Global
-- Therapeutic Assessment By Product Type: Mono, Combination,
Mono/Combination
-- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical,
Phase I, Phase II, Phase III
-- Therapeutics Assessment By Route of Administration: Oral, Intravenous,
Subcutaneous, Parenteral, Topical
-- Therapeutics Assessment By Molecule Type: Recombinant fusion proteins,
Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
-- Therapeutics Assessment By Mechanism of Action: Interferon alpha-beta
receptor antagonists, Cell death inhibitors, Cell death stimulants,
Antibody-dependent cell cytotoxicity, B-cell activation factor receptor
antagonists, Glucokinase stimulants, Dendritic cell inhibitors,
Complement factor D inhibitors, Complement C3 inhibitors, Proteasome
inhibitors, Natural killer cell replacements, Immunologic cytotoxicity;
T lymphocyte replacements
-- Key Lupus Nephritis Companies: AstraZeneca, Hoffmann-La Roche, Novartis,
Qilu Pharmaceutical, Vera Therapeutics, Conduit Pharmaceuticals, Amgen,
Johnson & Johnson, BeiGene, RemeGen, Argenx, Kyverna Therapeutics,
Cabaletta Bio, ImmPACT Bio, Alpine Immune Sciences, AlloSite
Therapeutics, iCell Gene Therapeutics, Caribou Biosciences, Adicet Bio,
Shenzhen Pregene Biopharma Co., Ltd., Resolve Therapeutics, BioAegis
Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, and others.
-- Key Lupus Nephritis Pipeline Therapies: Anifrolumab, Obinutuzumab,
Ianalumab, QLG1074, Atacicept, AZD1656, Daxdilimab, Nipocalimab,
Zanubrutinib, Telitacicept, Efgartigimod alfa, KYV-101, CABA-201,
IMPT-514, Povetacicept, ONT01, BCMA-CD19 cCAR T cells, CB-010, ADI-001,
PRG-2311, RSLV-621, Recombinant human plasma gelsolin, LN-008, TST 008,
and others.
Dive deep into rich insights for new drugs for lupus nephritis treatment, visit @ Lupus Nephritis Drugs [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Table of Contents
1. Lupus Nephritis Pipeline Report Introduction 2. Lupus Nephritis Pipeline Report Executive Summary 3. Lupus Nephritis Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Lupus Nephritis Clinical Trial Therapeutics 6. Lupus Nephritis Pipeline: Late-Stage Products (Pre- registration) 7. Lupus Nephritis Pipeline: Late-Stage Products (Phase III) 8. Lupus Nephritis Pipeline: Mid-Stage Products (Phase II) 9. Lupus Nephritis Pipeline: Early-Stage Products (Phase I) 10. Lupus Nephritis Pipeline Therapeutics Assessment 11. Inactive Products in the Lupus Nephritis Pipeline 12. Company-University Collaborations (Licensing/ Partnering) Analysis 13. Key Companies 14. Key Products in the Lupus Nephritis Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix
For further information on the lupus nephritis pipeline therapeutics, reach out @ Lupus Nephritis Treatment Drugs [https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Related Reports
Lupus Nephritis Epidemiology [https://www.delveinsight.com/report-store/lupus-nephritis-epidemiology-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Lupus Nephritis Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical, and forecasted lupus nephritis epidemiology in the 7MM.
Lupus Nephritis Market [https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Lupus Nephritis Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including NOVARTIS, MORPHOSYS, ASTRAZENECA, ROCHE, KEZAR LIFE SCIENCES, ALEXION PHARMACEUTICALS, CABALETTA BIO, among others.
Systemic Lupus Erythematosus Market [https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Systemic Lupus Erythematosus Pipeline [https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-pipeline-insight?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr]
Systemic Lupus Erythematosus Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including Yake Biotechnology, UCB, Sorrento Therapeutics, SinoMab Bioscience Ltd, Shanghai Junshi Biosciences, Sareum, Sanofi, Roche, Rheos Medicine, Resolve, Provention Bio, Pfizer, Novartis, Neovacs, Merck, Medsenic, Landos Biopharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, Janssen Research & Development, Janssen, InnoCare, ImmuPharma, I-MAB Biopharma, ILTOO, Idorsia Pharmaceuticals, Horizon Therapeutics, Genovax, Exinda Thearapeutics, Equillium, Eli Lilly and Company, Eisai, Daiichi Sankyo Company, Corestem, Corbus Pharmaceuticals, Citryll BV, Chipscreen Biosciences, Carna Bioscience, Bristol-Myers Squibb, Brickell Biotech, Boston Pharmaceuticals, Biogen, Athos Therapeutics, Asahi Kasei Pharma, Aria Pharmaceuticals, Antengene Therapeutics, Amgen, Alpine Immune Sciences, Akeso Biopharma, AbbVie, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com [mailto:info@delveinsight.com]
+14699457679
www.delveinsight.com [https://www.delveinsight.com/]
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg [https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg]
View original content:https://www.prnewswire.co.uk/news-releases/lupus-nephritis-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-30-companies-working-in-the-domain-302320390.html [https://www.prnewswire.co.uk/news-releases/lupus-nephritis-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-30-companies-working-in-the-domain-302320390.html]
Photo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg DelveInsight Business Research, LLP
